Đang hiển thị 1 - 6 kết quả của 6 cho tìm kiếm 'Halyna Pylypenko', thời gian truy vấn: 0.03s Tinh chỉnh kết quả
  1. 1
    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

    Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma Bằng Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau

    Được phát hành 2012-12-01
    lấy văn bản
    Bài viết
  2. 2
    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study

    Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study Bằng Philippe Moreau, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Grigoriy Rekhtman, Zvenyslava Masliak, Pawel Robak, Dixie-Lee Esseltine, Huaibao Feng, William Deraedt, Helgi van de Velde, Bertrand Arnulf

    Được phát hành 2015-05-01
    lấy văn bản
    Bài viết
  3. 3
    Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study

    Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study Bằng Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, Halyna Pylypenko, Noppadol Siritanaratkul, Juliana Pereira, Johannes Drach, Jiri Mayer, Rumiko Okamoto, Lixia Pei, Brendan Rooney, Andrew Cakana, Helgi van de Velde, Franco Cavalli

    Được phát hành 2017-05-01
    lấy văn bản
    Bài viết
  4. 4
    P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA

    P1034: FROM SNAPSHOT TO CONTINUUM: CUMULATIVE TIME IN RESPONSE AS AN EMERGING PROXY FOR THROMBOTIC RISK IN POLYCYTHEMIA VERA Bằng Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiří Mayer, Vera Yablokova, Kurt Krejcy, Victoria Empson, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian

    Được phát hành 2023-08-01
    lấy văn bản
    Bài viết
  5. 5
    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups

    Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups Bằng Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko, Lylia Sivcheva, Jiri Mayer, Vera Yablokova, Kurt Krejcy, Hans C. Hasselbalch, Robert Kralovics, Jean-Jacques Kiladjian, for the PROUD-PV Study Group

    Được phát hành 2020-12-01
    lấy văn bản
    Bài viết
  6. 6
    Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

    Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma Bằng Maria V. Mateos, Maria Gavriatopoulou, Thierry Facon, Holger W. Auner, Xavier Leleu, Roman Hájek, Meletios A. Dimopoulos, Sosana Delimpasi, Maryana Simonova, Ivan Špička, Ludĕk Pour, Iryna Kriachok, Halyna Pylypenko, Vadim Doronin, Ganna Usenko, Reuben Benjamin, Tuphan K. Dolai, Dinesh K. Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Z. Badros, Larry D. Anderson, Nizar J. Bahlis, Michele Cavo, Yi Chai, Jacqueline Jeha, Melina Arazy, Jatin Shah, Sharon Shacham, Michael G. Kauffman, Paul G. Richardson, Sebastian Grosicki

    Được phát hành 2021-04-01
    lấy văn bản
    Bài viết

Công cụ tìm kiếm: